382 related articles for article (PubMed ID: 17375074)
1. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
[TBL] [Abstract][Full Text] [Related]
2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
3. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity.
Curiel-Lewandrowski C; Mahnke K; Labeur M; Roters B; Schmidt W; Granstein RD; Luger TA; Schwarz T; Grabbe S
J Immunol; 1999 Jul; 163(1):174-83. PubMed ID: 10384114
[TBL] [Abstract][Full Text] [Related]
4. Programming the next generation of dendritic cells.
Carroll RG; June CH
Mol Ther; 2007 May; 15(5):846-8. PubMed ID: 17446871
[No Abstract] [Full Text] [Related]
5. Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors.
Campisano S; Mac Keon S; Gazzaniga S; Ruiz MS; Traian MD; Mordoh J; Wainstok R
Vaccine; 2013 Jan; 31(2):354-61. PubMed ID: 23146677
[TBL] [Abstract][Full Text] [Related]
6. [Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine].
Wang Z; You H; Song S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Apr; 29(4):379-83. PubMed ID: 23643168
[TBL] [Abstract][Full Text] [Related]
7. Rapid and efficient generation of lentivirally gene-modified dendritic cells from DC progenitors with bone marrow stromal cells.
Sumimoto H; Tsuji T; Miyoshi H; Hagihara M; Takada-Yamazaki R; Okamoto S; Ikeda Y; Takahashi T; Kawakami Y
J Immunol Methods; 2002 Dec; 271(1-2):153-65. PubMed ID: 12445738
[TBL] [Abstract][Full Text] [Related]
8. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
9. Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro.
Koya RC; Weber JS; Kasahara N; Lau R; Villacres MC; Levine AM; Stripecke R
Hum Gene Ther; 2004 Aug; 15(8):733-48. PubMed ID: 15319031
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
13. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
Klein C; Bueler H; Mulligan RC
J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863
[TBL] [Abstract][Full Text] [Related]
15. Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma.
Sundarasetty BS; Chan L; Darling D; Giunti G; Farzaneh F; Schenck F; Naundorf S; Kuehlcke K; Ruggiero E; Schmidt M; von Kalle C; Rothe M; Hoon DS; Gerasch L; Figueiredo C; Koehl U; Blasczyk R; Gutzmer R; Stripecke R
Gene Ther; 2015 Sep; 22(9):707-20. PubMed ID: 25965393
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses.
Weigel BJ; Nath N; Taylor PA; Panoskaltsis-Mortari A; Chen W; Krieg AM; Brasel K; Blazar BR
Blood; 2002 Dec; 100(12):4169-76. PubMed ID: 12393694
[TBL] [Abstract][Full Text] [Related]
17. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells.
Pincha M; Salguero G; Wedekind D; Sundarasetty BS; Lin A; Kasahara N; Brugman MH; Jirmo AC; Modlich U; Gutzmer R; Büsche G; Ganser A; Stripecke R
Gene Ther; 2011 Aug; 18(8):750-64. PubMed ID: 21412283
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
20. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
Li B; VanRoey MJ; Jooss K
Clin Immunol; 2007 May; 123(2):155-65. PubMed ID: 17320482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
